UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Act of 1934

(Amendment No. 1)

 

Clearmind Medicine Inc.

(Name of Issuer)

 

Common Shares, no par value

(Title of Class of Securities)

 

1850532047

(CUSIP Number)

 

April 6, 2023

(Date of event which requires filing of this statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1

NAME OF REPORTING PERSON

 

Medigus Ltd.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) 

(b)

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Israel

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

 

187,874 (1)  

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

187,874 (1)  

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

187,874 (1)

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

2.64% (2)

12

TYPE OF REPORTING PERSON

 

CO

 

(1)Consists of 187,874 Common Shares of the issuer held directly by Medigus Ltd.

 

(2)Based on 7,118,213 Common Shares issued and outstanding as of August 14, 2023, pursuant to information provided by the Issuer.

 

2

 

 

Item 1(a) Name of Issuer:

 

Clearmind Medicine Inc. (the “Issuer”)

 

Item 1(b) Address of Issuer’s Principal Executive Offices:

 

101 – 1220 West 6th Avenue, Vancouver, British Columbia, Canada

 

Item 2(a) Name of Person Filing:

 

Medigus Ltd.

 

Item 2(b) Address or Principal Business Office or, if none, Residence:

 

10 HaNechoshet Street, Tel-Aviv, 6971072, Israel

 

Item 2(c) Citizenship:

 

Israel

 

Item 2(d) Title of Class of Securities:

 

Common Share, no par value

 

Item 2(e) CUSIP Number:

 

1850532047

 

3

 

 

Item 3 If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:

 

Not applicable.

 

Item 4 Ownership.

 

See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.

 

Item 5 Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

 

Item 6 Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8 Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9 Notice of Dissolution of Group.

 

Not applicable.

 

Item 10 Certifications.

 

Not applicable.

 

4

 

 

SIGNATURES

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: September 5, 2023 Medigus Ltd.

 

  By: /s/ Tali Dinar
  Name:  Tali Dinar
  Title: Chief Executive Officer & Chief Financial Officer

 

 

5

 

 

 


Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Medigus Charts.
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Medigus Charts.